01815nas a2200205   4500008004100000022001400041245005100055210005100106260000800157300001200165490000700177520118300184653002001367653002101387653002801408653002601436653003401462100002701496856008601523       2021                        eng d  a0301-120800aOral insulin delivery using artificial peptide0 aOral insulin delivery using artificial peptide  cOCT  a408-4150 v583 aThe daily multiple insulin injection is the line of treatment for diabetes mellitus. As the oral insulin delivery mimics, the physiology of endogenous insulin secreted by pancreas. Recently, the search for suitable carrier to develop oral insulin delivery has been intensified. However, the carrier toxicity and very less bioavailability of insulin remains the major problem in the development of oral insulin delivery. Preparation of a non-covalent insulin-peptide complex using different peptide made of 16 to 20 L-amino acids studied to overcome the problem. The in vitro testing of insulin-peptide complex showed significant stability against the proteolytic enzyme. Whereas, in in vivo testing, the presence of 10-41% insulin in blood plasma observed after 30 to 60 min oral feeding of insulin-peptide complex. Results indicated that the peptide which showed moderate protection against pepsin and minor protection against trypsin and chymotrypsin has an important role in enhancing oral insulin bioavailability. However, the peptide which showed higher protection against trypsin and no protection against pepsin could not achieve significant oral insulin bioavailability.10aBioavailability10aCarrier toxicity10aInsulin-peptide complex10aOral insulin delivery10aProteolytic enzyme resistance1 aAdikane, Harshavardhan  uhttps://library.ncl.res.in/content/oral-insulin-delivery-using-artificial-peptide